New study tracks daily life with teplizumab for type 1 diabetes
NCT ID NCT07260110
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study follows 550 people with stage 2 type 1 diabetes in the U.S. to see how teplizumab treatment affects their quality of life, anxiety, and diabetes burden. Some participants received teplizumab, others did not. Researchers will compare the two groups to understand real-world experiences and disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site
RECRUITINGSan Francisco, California, 94107, United States
Conditions
Explore the condition pages connected to this study.